Anthropic Releases Improved Entry-Level AI Model Claude Instant 1.2


AI drug discovery heats up as outsiders enter: Anthropic builds wet lab, partners with Novo Nordisk and Bristol Myers Squibb, and acquires Coefficient Bio; ByteDance spin-off Xinsheng Lab completes first funding. AI mainly accelerates early R&D, shortening candidate screening and iteration, but costly, high-risk later stages remain unsolved.....
Societe Generale says expanding AI adoption offers significant cost savings of €500–600 million, with about €350 million planned by 2029. The bank is strategically partnering with Anthropic to deploy Claude models in phases.....
Claude Opus 5.5 (codename claude-wafer-eap) is in beta and may launch this Tuesday, skipping 5.2. Pricing: $4/M input tokens, $20/M output, below Opus 5's $5/$25, seen as directly targeting GPT-6.....
Anthropic may skip Opus 5.2, testing Opus 5.5 codenamed claude-wafer-eap, likely launching Tuesday. Priced at $4/M input and $20/M output tokens, targeting GPT-6; rumored to beat Astra. Claude Fable 5.2 also in prep amid pre-IPO moves.....
Anthropic plans to postpone its IPO from October to November to include Q3 results, proving competitiveness and strengthening market confidence. Investors hold high valuation expectations with strong demand.....